Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects
humoral immune response after vaccination. It remains unclear whether RTX-treated …

Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T …

Objective Antibody response to the messenger RNA (mRNA) COVID‐19 vaccine has been
shown to be diminished in rituximab (RTX)–treated patients. We undertook this study to …

Objective Patients with autoimmune inflammatory rheumatic diseases receiving rituximab
(RTX) therapy are at higher risk of poor COVID‐19 outcomes and show substantially …

Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …

1 Rimar D, Butbul Aviel Y, Gefen A, et al. Autologous hematological stem cell transplantation
for systemic sclerosis in Israel. Isr Med Assoc J 2020; 22: 104–10. 2 Kowal-Bielecka O …

SARS-CoV-2 mRNA vaccination elicited high immunogenicity in immunocompetent people
in the original vaccine trials, 1 2 though recent studies have shown blunted immunogenicity …

Objective B cell depletion is an established therapeutic principle in a wide range of
autoimmune diseases. However, B cells are also critical for inducing protective immunity …

Objective With a vaccine effectiveness of 95% for preventing coronavirus disease 2019
(COVID‐19), Pfizer‐BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe …

Objective To assess the kinetics of the humoral and cell-mediated responses after severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in rheumatoid arthritis …